#South Korea #Seoul #Eisai #Leqembi #Alzheimer's

Leqembi® Launched in South Korea

BioArctic AB's partner, Eisai, has recently announced the launch of Leqembi® (scientific name: lecanemab) in South Korea. This marks a significant milestone in the fight against Alzheimer's disease, offering hope to many. Approved in May 2024, Leqembi is specifically designed for adults experiencing mild cognitive impairment due to Alzheimer’s disease (AD) or mild Alzheimer’s dementia (early AD).

The Need for Effective Alzheimer’s Treatment

As reported in 2021, there were approximately 900,000 individuals living with dementia in South Korea. With one in ten people over 65 suffering from dementia—primarily Alzheimer’s—it becomes increasingly vital to develop effective treatment options. Approximately 70% of dementia cases in South Korea are attributed to Alzheimer’s, emphasizing the importance of Leqembi’s timely arrival in the healthcare landscape.

How Leqembi® Works

Leqembi's unique mechanism involves selectively binding to soluble amyloid-beta (Aβ) aggregates, known as protofibrils, and their insoluble counterparts, which are key components of Aβ plaques that accumulate in Alzheimer’s. By reducing both Aβ protofibrils and plaques in the brain, Leqembi represents the first treatment proven to slow disease progression and cognitive decline.

The Collaboration Behind Leqembi

This groundbreaking treatment stems from a longstanding partnership between BioArctic and Eisai. Lecanemab's development was initially inspired by research from Professor Lars Lannfelt, who identified the Arctic mutation associated with Alzheimer’s disease. Eisai has taken the lead in the clinical development and commercialization efforts, while BioArctic retains rights in the Nordic region, as they prepare for their joint launch pending regulatory approval.

Clinical Approval and Safety

Leqembi is already approved in multiple countries, including the U.S., Japan, China, and the U.K., addressing the growing need for effective Alzheimer’s therapies worldwide. The drug's approval stemmed primarily from the Phase 3 results of Eisai’s Clarity AD trial, which demonstrated significant reductions in cognitive decline among participants. It’s important to note that while common adverse effects include infusion-related reactions and headaches, these are relatively mild compared to the benefits of the treatment.

Future Perspectives and Ongoing Research

Eisai is committed to expanding the reach of Leqembi, with applications submitted for approval in 17 additional countries, highlighting the growing global recognition of its potential. Additionally, ongoing clinical studies, such as the AHEAD 3-45 study focusing on individuals with preclinical Alzheimer’s and the Tau NexGen study for dominantly inherited Alzheimer’s, showcase the commitment to advancing understanding and treatment of Alzheimer's disease.

Conclusion

The launch of Leqembi® in South Korea is a promising development for Alzheimer’s patients and their families. As this treatment hits the market, expectations are high for improved management of Alzheimer’s disease, making significant strides towards better healthcare outcomes in the context of neurodegenerative diseases. With continued research and collaboration between BioArctic and Eisai, the future looks hopeful for those affected by Alzheimer's.